Mergers & Acquisitions - Merck & Co, Mergers & Acquisitions

Filter

Popular Filters

Merck & Co sells ophthalmic brands and Colorado biologicals unit

Merck & Co sells ophthalmic brands and Colorado biologicals unit

13-05-2014

US pharma giant Merck & Co has entered into two more divestment transactions, following the recent sell-off…

KBI BiopharmaMerck & CoMergers & AcquisitionsOphthalmicsPharmaceuticalProductionSanten Pharmaceuticals

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

Amount of foreign direct investment proves India’s attraction to Big Pharma despite protestations on IP

31-03-2014

Multinational drugmakers might be crying themselves hoarse that India does not protect innovation - that…

Asia-PacificBristol-Myers SquibbFinancialGlaxoSmithKlineIndiaMerck & CoMergers & AcquisitionsMylan LaboratoriesPatentsPharmaceuticalSanofi

Are you overlooking the “X Factor” in Biopharma M&A? asks JLL expert

Are you overlooking the “X Factor” in Biopharma M&A? asks JLL expert

12-03-2014

When Merck & Co acquired Schering-Plough in 2009, the corporate real estate team reduced the combined…

ManagementMerck & CoMergers & AcquisitionsPharmaceutical

Alnylam to acquire Merck’s Sirna Therapeutics

Alnylam to acquire Merck’s Sirna Therapeutics

13-01-2014

US RNAi therapeutics specialist Alnylam Pharmaceuticals says it has reached agreement to acquire US pharma…

Alnylam PharmaceuticalsBiotechnologyMerck & CoMergers & AcquisitionsSirna Therapeutics

Akorn shells out $52.8 million for rights to three Merck drugs

Akorn shells out $52.8 million for rights to three Merck drugs

18-11-2013

USA-based niche generic drugmaker Akorn has acquired from pharma giant Merck & Co the US rights to three…

AkornAzaSiteCosoptGenericsMerck & CoMergers & AcquisitionsNorth AmericaOphthalmics

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

05-02-2013

Aduro BioTech, a privately-held, US venture capital backed biotechnology company, says it has acquired…

Aduro BioTechAspen PharmacareBioSante PharmaceuticalsBiotechnologyGenericsGVAXImmunologicalsMerck & CoMergers & AcquisitionsOncologyVaccines

Merck & Co reportedly eyeing Micro Labs buy

22-06-2012

US drugs giant Merck & Co has begun talks with privately-held Indian drugmaker Micro Labs to acquire…

GenericsMerck & CoMergers & AcquisitionsMicro LabsPharmaceutical

Amylin said to be attracting several Big Pharma suitors

16-05-2012

US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), which earlier this year rebuffed a $22 per share…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbMerck & CoMergers & AcquisitionsPfizerPharmaceuticalRocheSanofiTakeda Pharmaceuticals

Merck & Co sets up marketing JV in Brazil

16-02-2012

Merck & Co (NYSE: MRK) says it has formed a new joint venture with Supera Farma Laboratorios, a Brazilian…

CristaliaEurofarmaGenericsMarkets & MarketingMerck & CoMergers & AcquisitionsPharmaceuticalSouth AmericaSupera Farma

Merck & Co out to lead in hepatitis C

12-01-2012

US drugs giant Merck & Co (NYSE: MRK) aims to become a leader in the hepatitis C space, the company’s…

Anti-viralsMerck & CoMergers & AcquisitionsPharmaceuticalResearch

Sanofi to top Pfizer as number one for global pharma sales

01-11-2011

French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world’s pharmaceuticals…

FinancialGlobalJohnson & JohnsonMarkets & MarketingMerck & CoMergers & AcquisitionsNovartisNovo NordiskPfizerPharmaceuticalSanofiTakeda PharmaceuticalsTeva Pharmaceutical Industries

Parexel

Parexel

Back to top